Table 3.
Proportion (%) of patients with improved or unchanged ultrasonographic findings after 24 weeks of PPC treatment, according to the number of comorbidities
| Features—% | One comorbidity (n=570) |
Two comorbidities (n=1108) |
Three comorbidities (n=868) |
Four comorbidities (n=281) |
||||
| Improved | No change | Improved | No change | Improved | No change | Improved | No change | |
| Diffuse liver hyperechogenicity | 69.3 | 30.7 | 68.8 | 31.2 | 67.2 | 32.8 | 69.0 | 31.0 |
| Heterogeneous structure of the liver* | 35.6 | 64.4 | 45.3 | 54.5 | 45.3 | 54.7 | 38.8 | 60.8 |
| Indistinctness and/or underlined vascular pattern | 15.4 | 84.6 | 21.1 | 78.9 | 26.5 | 73.5 | 24.4 | 75.6 |
| Distal echo signal attenuation | 14.6 | 85.4 | 20.0 | 80.0 | 23.8 | 76.2 | 25.3 | 74.7 |
*Worsening of ‘heterogeneous structure of the liver’ occurred in 0.2% of patients with two comorbidities and in 0.4% of patients with four comorbidities.
PPC, polyenylphosphatidylcholine.